MIRA
INFORM REPORT
|
Report Date : |
05.07.2011 |
IDENTIFICATION DETAILS
|
Name : |
ASTRAZENECA PHARMA INDIA LIMITED |
|
|
|
|
Registered Office : |
‘Avishkar’ Off |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2009 |
|
|
|
|
Date of Incorporation : |
11.07.1979 |
|
|
|
|
Com. Reg. No.: |
08 – 3563 |
|
|
|
|
Capital
Investment/ Paid-up Capital: |
Rs.50.000
Millions |
|
|
|
|
CIN No.: [Company
Identification No.] |
L24231KA1979PLC003563 |
|
|
|
|
Legal Form : |
A Public Limited Liability Company. The company shares are listed on
stock exchange |
|
|
|
|
Line of Business : |
The
Company's principal activity are to research, develop and market medicines for
serious health conditions |
|
|
|
|
No. of Employees: |
Not
Available |
RATING & COMMENTS
|
MIRA’s Rating : |
A (64) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
USD 5800000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well established and reputed company having fine track.
Financial position of the company appears to be sound. Directors are reported
to be experienced and respectable businessmen. Trade relations are reported
as fair. Business is active. Payments are reported to be regular and as per
commitments. The company can be considered good for normal business dealings at
usual trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – April 1, 2010
|
Country Name |
Previous Rating (31.12.2009) |
Current Rating (01.04.2010) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
LOCATIONS
|
Registered/Corporate Office : |
‘Avishkar’ Off |
|
Tel. No.: |
91-80-23622020 / 27/ 67748000 |
|
Fax No.: |
91-80-23622015 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Factory : |
12th Mile on |
|
Tel. No.: |
91-80-28460172 |
|
Fax No.: |
91-80-28462208 |
|
|
|
|
Sales Outlet: |
Located at:
|
DIRECTORS
AS ON 31.12.2009
|
Name : |
Mr. D.E. Udwadia |
|
Designation : |
Chairman |
|
|
|
|
Name : |
Mr. K.S. Shah |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. Ian Brimicombe |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. Bhasker V. Iyer |
|
Designation : |
Director (Till 23.02.2010) |
|
|
|
|
Name : |
Mr. Francis McNamara III |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. Luigi Felice La Corte |
|
Designation : |
Director (w.e.f. 25.03.2010) |
|
|
|
|
Name : |
Mr. Anandh Balasundaram |
|
Designation : |
Managing Director |
KEY EXECUTIVES
|
Name : |
Mr. N. R. Srinivasan |
|
Designation : |
Company Secretary |
|
|
|
|
Name : |
Mr. S.J. V Chellilah |
|
Designation : |
Chief Financial Officer |
|
|
|
|
Audit Committee: |
|
|
|
|
|
Shareholders’/ Investors’ Grievance Committee |
|
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
AS ON (31.03.2011)
|
Names of Shareholders |
No. of Shares |
Percentage of
Holding |
|
(A) Shareholding of Promoter and Promoter Group |
|
|
|
|
|
|
|
|
|
|
|
|
22,499,950 |
90.00 |
|
|
22,499,950 |
90.00 |
|
Total shareholding of Promoter and Promoter Group (A) |
22,499,950 |
90.00 |
|
(B) Public Shareholding |
|
|
|
|
|
|
|
|
593,393 |
2.37 |
|
|
375 |
- |
|
|
7,100 |
0.03 |
|
|
600,868 |
2.40 |
|
|
|
|
|
|
81,268 |
0.33 |
|
|
|
|
|
|
1,718,081 |
6.87 |
|
|
64,340 |
0.26 |
|
|
35,493 |
0.14 |
|
|
2,331 |
0.01 |
|
|
32,887 |
0.13 |
|
|
275 |
- |
|
|
1,899,182 |
7.60 |
|
Total Public shareholding (B) |
2,500,050 |
10.00 |
|
Total (A)+(B) |
25,000,000 |
100.00 |
|
(C) Shares held by Custodians and against which Depository Receipts
have been issued |
- |
- |
|
|
- |
- |
|
|
- |
- |
|
|
- |
- |
|
Total (A)+(B)+(C) |
25,000,000 |
100.00 |
(1) Indian
Bodies Corporate
Individual shareholders holding nominal
share capital up to Rs. 0.100 MillionBUSINESS DETAILS
|
Line of Business : |
The
Company's principal activity are to research, develop and market medicines
for serious health conditions |
|
|
|
|
|
|
Products : |
ITC CODE |
Product
Description |
|
30049099 |
Meropenem |
|
|
30044030 |
Codiene Phosphate |
|
|
30049074 |
Metoprolol Tartrate |
|
PRODUCTION STATUS (31.12.2009)
|
Particulars |
Unit |
Licensed
Capacity |
Installed
Capacity |
Actual
Production |
|
Bulk Drugs |
Tonnes Million units Gms |
540.65 250.00 2950.00 |
** ** ** |
2.858 -- 1603.52 |
|
2. Formulations + a) Liquids |
|
++ |
|
|
|
|
Kilo Ltrs Tonnes Million bottles |
364.00 2.17 3.50 |
2500.00 |
1274.03 -- -- |
|
b) Tablets and Capsules |
Million nos. Tonnes |
614.30 47.49 |
690.00 |
429.36 -- |
|
c) Injectables |
Million nos. Kilo Ltrs Tonnes |
4.90 50.00 0.15 |
3.00 |
19.87 -- -- |
|
d) ointments |
Tonnes Million nos. |
-- 3.00 |
260.75 |
202.17 -- |
|
e) Inhalation Products |
Gms Million nos. |
2000.00 0.62 |
-- -- |
-- 0.21 |
Notes:
* Installed capacities are as certified by the management and relied on
by the auditors being a technical matter.
** Installed capacities cannot be determined as the facilities installed
serve multi-purposes and will vary according
to product mix.
# Includes units captively consumed in the manufacture of formulations.
+ Licensed capacities for formulations do not include either capacities
available under various exemption notifications or capacities arising from
licences for manufacture of bulk drugs where capacities for dosage forms are
not specified.
++ The Company also holds a registration certificate for formulations
where licensed capacities are not mentioned. However, as per various
notifications issued by Central Government, applications have been made by the
Company to authorities concerned for the recognition of installed capacities
for formulations and for endorsement of such capacities on the registration
certificate. The applications are pending with the relevant authorities.
*** Production includes samples produced. It also includes products
manufactured through outside processors.
GENERAL INFORMATION
|
Bankers : |
|
||||||||||||
|
|
|
||||||||||||
|
Facilities: |
|
||||||||||||
|
|
|
|
Banking Relations
: |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
BSR and Company Chartered Accountant |
|
Address : |
|
|
Tel. No.: |
|
|
Mobile No.: |
|
|
Fax No.: |
|
|
E-Mail : |
|
|
|
|
|
Collaborators : |
|
|
|
|
|
Holding Company: |
AstraZeneca Pharmaceuticals AB, |
|
|
|
|
Ultimate Holding Company: |
AstraZeneca Plc, |
|
|
|
|
Fellow Subsidiaries : |
Tel: 91-80-23621-212 Fax: 91-80-23621-214 |
CAPITAL STRUCTURE
AS ON (31.12.2009)
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
25000000 |
Equity Share |
Rs.2/- Each |
Rs.50.000 Millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
25000000 |
Equity Share |
Rs.2/- Each |
Rs.50.000
Millions |
NOTE:
[Of the above 12,500,000 (previous year: 12,500,000) equity shares of Rs 2 each were allotted as fully paid-up bonus shares by capitalisation of general reserve]
[Of the above, 22,499,950 (previous year: 22,499,950) equity
shares of Rs 2 each are held by the holding
company AstraZeneca Pharmaceuticals AB, Sweden. AstraZeneca PLC,
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.12.2009 |
31.12.2008 |
31.12.2007 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
50.000 |
50.000 |
50.000 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
1395.182 |
1111.497 |
1543.095 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
1445.182 |
1161.497 |
1593.095 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
0.000 |
625.000 |
0.000 |
|
|
2] Unsecured Loans |
0.000 |
0.000 |
0.000 |
|
|
TOTAL BORROWING |
0.000 |
625.000 |
0.000 |
|
|
DEFERRED TAX LIABILITIES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
1445.182 |
1786.497 |
1593.095 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
300.182 |
303.644 |
330.795 |
|
|
Capital work-in-progress |
3.254 |
0.859 |
1.544 |
|
|
|
|
|
|
|
|
INVESTMENT |
0.057 |
0.057 |
0.067 |
|
|
DEFERREX TAX ASSETS |
29.400 |
23.712 |
17.263 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
352.001
|
340.064 |
237.879 |
|
|
Sundry Debtors |
682.061
|
501.362 |
470.718 |
|
|
Cash & Bank Balances |
682.354
|
1438.039 |
1110.354 |
|
|
Other Current Assets |
262.603
|
199.310 |
210.437 |
|
|
Loans & Advances |
26.754
|
80.512 |
80.553 |
|
Total
Current Assets |
2005.773
|
2559.287 |
2109.941 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
121.570
|
74.330 |
41.225 |
|
|
Other Current Liabilities |
340.416
|
400.686 |
254.428 |
|
|
Provisions |
431.498
|
626.046 |
570.862 |
|
Total
Current Liabilities |
893.484
|
1101.062 |
866.515 |
|
|
Net Current Assets |
1112.289
|
1458.225 |
1243.426 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
1445.182 |
1786.497 |
1593.095 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.12.2009 |
31.12.2008 |
31.12.2007 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
3855.212 |
3397.685 |
2973.137 |
|
|
|
Services Income |
111.121 |
144.962 |
65.252 |
|
|
|
Other Income |
57.440 |
138.758 |
97.239 |
|
|
|
TOTAL (A) |
4023.773 |
3681.405 |
3135.628 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Materials Cost |
1209.594 |
995.072 |
941.715 |
|
|
|
Other Expenses |
1868.120 |
1425.180 |
1182.026 |
|
|
|
TOTAL (B) |
3077.714 |
2420.252 |
2123.741 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
946.059 |
1261.153 |
1011.887 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
1.370 |
48.630 |
0.000 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
944.689 |
1212.523 |
1011.887 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
60.767 |
68.763 |
58.399 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
883.922 |
1143.760 |
953.488 |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
307.750 |
405.408 |
338.902 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-H) (I) |
576.172 |
738.352 |
614.586 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
409.202 |
495.916 |
381.520 |
|
|
|
|
|
|
|
|
|
Less |
APPROPRIATIONS |
|
|
|
|
|
|
|
Transfer to General Reserve |
57.617 |
73.835 |
61.459 |
|
|
|
Transfer to Debenture Reserve |
-- |
312.500 |
-- |
|
|
|
Transfer from Debenture redemption reserve |
(312.500) |
-- |
-- |
|
|
|
Proposed Dividend |
250.000 |
375.000 |
375.000 |
|
|
|
Tax on Proposed Dividend |
42.488 |
63.731 |
63.731 |
|
|
BALANCE CARRIED
TO THE B/S |
947.769 |
409.202 |
495.916 |
|
|
|
|
|
|
|
|
|
|
EARNINGS IN
FOREIGN CURRENCY |
|
|
|
|
|
|
|
Export Earnings |
175.490 |
83.794 |
23.058 |
|
|
|
Service income (Gross) |
111.121 |
144.961 |
65.252 |
|
|
|
Processing Income
(Gross) |
0.000 |
12.418 |
0.000 |
|
|
TOTAL EARNINGS |
286.611 |
241.173 |
88.310 |
|
|
|
|
|
|
|
|
|
|
IMPORTS |
|
|
|
|
|
|
|
Raw and packing
materials |
205.810 |
138.676 |
89.370 |
|
|
|
Spare parts |
0.916 |
0.271 |
0.156 |
|
|
|
Capital goods |
4.546 |
0.395 |
3.287 |
|
|
TOTAL IMPORTS |
211.272 |
139.342 |
92.813 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
23.05 |
29.53 |
24.58 |
|
QUARTERLY RESULTS
|
PARTICULARS |
30.06.2010 |
30.09.2010 |
31.12.2010 |
31.03.2011 |
|
Net Sales |
1109.120 |
1260.060 |
1325.230 |
1266.770 |
|
Total Expenditure |
991.130 |
990.110 |
894.080 |
1100.800 |
|
PBIDT (Excl OI) |
117.990 |
269.950 |
431.150 |
165.970 |
|
Other Income |
10.670 |
8.970 |
15.330 |
21.980 |
|
Operating Profit |
128.650 |
278.920 |
446.480 |
187.950 |
|
Interest |
0.000 |
0.000 |
0.000 |
0.000 |
|
Exceptional Items |
0.000 |
0.000 |
0.000 |
0.000 |
|
PBDT |
128.650 |
278.920 |
446.480 |
187.950 |
|
Depreciation |
17.580 |
18.690 |
18.540 |
17.560 |
|
Profit Before Tax |
111.070 |
260.230 |
427.950 |
170.390 |
|
Tax |
37.930 |
84.970 |
144.730 |
86.850 |
|
Provisions and contingencies |
0.000 |
0.000 |
0.000 |
0.000 |
|
Profit After Tax |
73.150 |
175.260 |
283.220 |
83.540 |
|
Extraordinary Items |
0.000 |
0.000 |
0.000 |
0.000 |
|
Prior Period Expenses |
0.000 |
0.000 |
0.000 |
0.000 |
|
Other Adjustments |
0.000 |
0.000 |
0.000 |
0.000 |
|
Net Profit |
73.150 |
175.260 |
283.220 |
83.540 |
KEY RATIOS
|
PARTICULARS |
|
31.03.2009 |
31.03.2008 |
31.03.2007 |
|
PAT / Total Income |
(%) |
14.32
|
20.06 |
19.60 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
22.93
|
33.66 |
32.07 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
38.33
|
40.02 |
39.07 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.61
|
0.98 |
0.60 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
0.62
|
0.94 |
0.54 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
2.24
|
2.33 |
2.43 |
LOCAL AGENCY FURTHER INFORMATION
SALES AND
MARKETING
The Company registered a healthy growth of 13.5% (excluding export
sales) over the previous year with sales of
Rs. 3679 Millions (excluding export sales).
As a part of the growth strategy, 7 new products were launched in year
2009. The Company also launched an AstraZeneca original research brand, viz.
Crestor (Rosuvastatin) in the
Cardiovascular Therapeutic Area for Lipid Management. The new products launched
under the Company’s growth strategy have contributed to the overall performance
of the Company, within six months of their respective launch.
During the year, the Cardiovascular Therapeutic Area (TA) grew by 11%.
‘Seloken XL’ and ‘Selomax’ continued
to show good performance. The launch of ‘Crestor’ further boosted the
performance of this TA.
Infection TA grew by 19%. Both ‘Meronem’ and ‘Vancocin’ registered
double-digit growth and ‘Meronem’ continued to be the No. 1 hospital product.
‘Neksium’, the Company’s product in the Gastrointestinal TA posted an
impressive growth of 36%, during the year.
The Local Anaesthesia TA continued to grow with both ‘Xylocaine’ and
‘Sensorcaine’ registering steady growth.
MANAGEMENT
DISCUSSION and ANALYSIS REPORT
Industry structure
and developments
During the financial year 2009, the total Indian Pharmaceutical market
was over Rs. 400,517 Mio and has grown by 17%. The IMS ORG Report shows that
the Company has a market share of about 0.60%.
Opportunities and
threats / Risk and concerns
The efforts being put in by the industry bodies to bring in certain
changes in the current Patent Act are yet to materialise. The Central Government
is still to take action on the report submitted by Inter-ministerial Committee
on Regulatory data protection. The draft Pharma Policy has been referred to a
Group of Ministers to submit its report before implementation. The proposal in
the draft policy to expand the number of drugs covered by Drug Price Control
Order (DPCO) by including drugs listed in national list of essential medicines,
if accepted could be an area of concern for the pharmaceutical Industry in
India. It is hoped that Government would take right steps to encourage
innovation in the country by suitably revising the relevant policies and
guidelines in this area.
Segment-wise or
product-wise performance
The Company has two business segments, namely:
• Healthcare
• Clinical Trial Services
The healthcare division engages in the manufacture and sale of
pharmaceutical products. During the year, the healthcare division generated
total revenue of Rs.3858 Millions out of which domestic sales were of Rs.
3682.50 Millions and exports sales of Rs. 175.50 Millions.
The Clinical Trial division renders clinical trial services on
pharmaceutical products to its group companies. During
the year the division generated revenue from export of services of Rs.
111.12 Millions.
A separate disclosure as required under Accounting Standard 17 - Segment
Reporting, is being made in the financial statements.
Outlook
The Company, with a view to significantly enhance its market presence,
has embarked on a growth strategy to expand its product portfolio by launching
both AZ Global brands as well as local brands coupled with expansion in the
field force over the next two to three years. In the Year 2009, the Company
significantly increased its market presence by doubling its field force and
launched 8 products including Global blockbuster, Crestor. In the Year 2010,
the Company intends to continue expanding its product portfolio by introducing
new brands for the Indian market.
Contingent
liabilities and commitments:
(Rs.
In Millions)
|
Particular |
31.12.2009 |
31.12.2008 |
|
Claims
against the Company not acknowledged as debts
in respect of: |
|
|
|
a) Demands for payments into the credit of the Drugs
Prices Equalisation Account under Drugs (Price Control) Order, 1979, which
are being contested by the Company (including a case involving a demand of
Rs.5.107 Millions, where the Central Government has referred the matter to
the division bench of the honourable High Court of Karnataka, which has been
rejected by the division bench. The Central Government has now made an
application for transfer of this matter to the Supreme Court). On another
matter of Ibuprufen, the Company has received a further demand of Rs 10.051
Millions towards interest for the period from 1986 to 2004, which is also
contested and disputed by the Company. Contingent liability is inclusive of
interest accrued on the demand. |
0.000 |
27.891 |
|
Excise and service tax
matters |
1.696 |
1.696 |
|
Other
commitments / contingent liability |
|
|
|
a) In respect of bank
guarantees |
9.437 |
6.639 |
|
b) Estimated amount of contracts
remaining to be executed on capital account (net of advances) and not
provided for |
3.481 |
5.702 |
FIXED ASSETS:
- Freehold land
- Buildings
- Roads and culverts
- Plant and machineries
- Vehicles
- Furniture and fixtures
- Office equipment
- Technical know-how and trademark
FINANCIAL RESULTS FOR THE QUARTER AND FIFTEEN MONTHS ENDED 31.03.2011
|
Particulars |
3 Months Ended |
3 Months Ended |
Year to Debts Figures for the current period |
|
31.03.2011 (Unaudited) |
31.03.2010 (Unauditd) |
31.03.2011 (Audited) |
|
|
a)Net Sales |
1233.047 |
922.841 |
5743.620 |
|
b) Other Operating Income – Service Income |
33.721 |
56.238 |
195.630 |
|
2. Expenditure |
|
|
|
|
a. (Increase)/Decrease
in stock in trade and work in progress |
[9.978] |
[40.106] |
[135.895] |
|
b. Consumption of
raw materials |
164.044 |
132.998 |
760.440 |
|
c. Purchase of
traded goods |
241.888 |
202.281 |
1168.117 |
|
d. Employee Cost
|
362.961 |
268.050 |
1504.976 |
|
e. Depreciation /
Amortisation |
17.563 |
15.761 |
88.128 |
|
f. Other expenditure |
321.877 |
365.750 |
1607.449 |
|
Total
Expenditure |
1118.355 |
944.734 |
4993.215 |
|
|
|
|
|
|
Profit
from Operations before Other Income, Interest and Exceptional Items |
148.413 |
34.345 |
947.035 |
|
|
|
|
|
|
Other Income |
21.979 |
5.864 |
82.814 |
|
|
|
|
|
|
Profit
before Interest & Exceptional Items |
170.392 |
40.209 |
1003.849 |
|
|
|
|
|
|
Interest (Net) |
-- |
-- |
-- |
|
|
|
|
|
|
Profit/
(Loss) after interest but before Exceptional Items |
170.392 |
40.209 |
1003.849 |
|
|
|
|
|
|
Exceptional Items – Gain / (Loss) (Refer
note no. 3) |
-- |
-- |
-- |
|
|
|
|
|
|
Profit
/Loss from Ordinary Activities before tax |
170.392 |
40.209 |
1003.849 |
|
|
|
|
|
|
Tax Expenses |
86.853 |
14.069 |
388.552 |
|
|
|
|
|
|
Net Profit from the
ordinary activities after tax |
83.539 |
28.140 |
641.287 |
|
|
|
|
|
|
Paid-up equity share capital (Face Value
of Rs.2/- each ) |
50.000 |
50.000 |
50.000 |
|
|
|
|
|
|
Reserves excluding Revaluation Reserves as
per balance sheet of previous accounting year |
-- |
-- |
1746.896 |
|
|
|
|
|
|
Basic and Diluted Earnings Per Share (EPS)
|
3.34 |
1.05 |
26.85 |
|
|
|
|
|
|
Promoters
and promoter group shareholding |
|
|
|
|
a. Pledged/Encumbered |
|
|
|
|
Number Of shares |
-- |
-- |
-- |
|
Percentage Of Shares (as a %of the total
shareholding of promoter and promoter group) |
-- |
-- |
-- |
|
Percentage Of Shares (as a % of the total
share capital of the company) |
-- |
-- |
-- |
|
|
|
|
|
|
b. Non-encumbered |
|
|
|
|
Number Of shares |
22499950 |
22499950 |
22499950 |
|
Percentage Of Shares (as a % of the total
shareholding of promoter and promoter group) |
100% |
100% |
100% |
|
Percentage Of Shares (as a % of the total
share capital of the company) |
89.99% |
89.99% |
89.99% |
SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED
|
Particulars |
3 Months Ended |
3 Months Ended |
Year to Debts Figures for the current period |
|
31.03.2011 (Unaudited) |
31.03.2010 (Unauditd) |
31.03.2011 (Audited) |
|
|
Segment Revenue |
|
|
|
|
a) Healthcare |
1233.622 |
923.364 |
5746.443 |
|
b) Others |
33.721 |
56.238 |
186.639 |
|
Total |
1267.343 |
979.602 |
5943.073 |
|
Less: Inter- Segment Revenue |
-- |
-- |
-- |
|
Net Income from Operations |
1267.343 |
979.602 |
5943.073 |
|
|
|
|
|
|
2. Segment Results |
|
|
|
|
Profit before Tax and Interest |
|
|
|
|
a) Healthcare |
153.944 |
30.570 |
938.559 |
|
b) Others |
[4.955] |
4.298 |
11.208 |
|
Total |
148.988 |
34.868 |
949.858 |
|
Add: Other Income |
21.404 |
5.341 |
58.991 |
|
Less: Interest |
-- |
-- |
-- |
|
Total Profit Before Tax |
170.392 |
40.208 |
1009.849 |
|
|
|
|
|
|
3. Capital Employed |
|
|
|
|
a) Healthcare |
1212.233 |
934.846 |
1212.233 |
|
b) Others |
64.423 |
[2.171] |
64.420 |
|
c) Unallocated |
520.243 |
538.847 |
520.243 |
|
Total |
1796.896 |
1471.322 |
1796.896 |
AS PER WEBSITE
PROFILE
AstraZeneca
AstraZeneca
With a strong pan-India presence, they’re one of
the fastest growing multinational company in
NEWS:
Genetic substudy shows fewer major cardiovascular
events with ticagrelor (brilinta) regardless of relevant genetic variability in
ACS patients
Published date :
Aug 29, 2010
A new genetic substudy of PLATO (A Study of
PLATelet Inhibition and Patient Outcomes) showed that the effects on a combined
primary endpoint of cardiovascular death, myocardial infarction, or stroke seen
in Acute Coronary Syndromes (ACS) patients who received the investigational
oral antiplatelet treatment, ticagrelor (BRILINTA™), were maintained, whether
or not they had the genetic variability that has been previously shown to
affect a patient’s response to clopidogrel. The substudy is the first to look
at both efficacy and bleeding endpoints of ACS patients treated with ticagrelor
who carry variations in the CYP2C19 and ABCB1 genes. The data were presented
today at the European Society of Cardiology (ESC) congress in
CYP2C19
Regardless of the CYP2C19 genotype, the primary
outcome occurred less often with ticagrelor versus clopidogrel (interaction
p=0.46). Ticagrelor event rates were 8.6% per year in carriers and 8.8% per
year in non-carriers of CYP2C19 loss-of-function genotype. For clopidogrel
patients that carried the CYP2C19 loss-of-function allele, there was a 11.2%
per year event rate, compared to 10.0% per year for patients without the loss-of-function
allele. Similar to the overall PLATO study, total major bleeding did not
significantly differ between ticagrelor and clopidogrel regardless of CYP2C19
genotype.
ABCB1
The genetic substudy also investigated ticagrelor
and clopidogrel treatment outcomes in the three genetic groupings of the ABCB1
gene group; these were defined as high, intermediate and low expressions of
ABCB1, respectively. The primary efficacy event rates for ticagrelor
were: 9.5% per year for low, 8.5% per year for intermediate, and 8.8% per year
for high expression groups. Primary efficacy event rates for clopidogrel were:
10.5% per year for low, 9.8% per year for intermediate, and 11.9% per year for
high expression groups. There was no relationship between the ABCB1 genotype and
bleeding.
“This substudy is the largest database of ACS
patients to date to examine the impact of genetic make-up on response to oral
antiplatelet treatment. As this substudy showed, the effects seen with
ticagrelor were independent of genetic variability in CYP2C19 or ABCB1,” said
Professor Lars Wallentin, primary investigator of the PLATO genetic substudy
and Professor of Cardiology and Research Director at the Uppsala University,
Sweden.
The substudy was designed to explore the
interaction of CYP2C19 and ABCB1 genes on ticagrelor and clopidogrel efficacy
and safety. 10,285 ACS patients were genotyped for CYP2C19 and ABCB1 status. On
a background of aspirin, patients in the ticagrelor group were given a 180 mg
loading dose and a 90 mg twice-daily maintenance dose, while patients in the
clopidogrel group were given a 300 mg to 600 mg loading dose and 75 mg
once-daily maintenance dose, for 6 to 12 months.
About ACS
ACS is an umbrella term for conditions that result from
a reduction in blood flow to the heart muscle. These conditions range from
unstable angina (UA/chest pain) to myocardial infarction (MI/heart attack):
STEMI is a type of heart attack in which the
coronary artery is generally blocked off by a blood clot, and as a result
virtually all the heart muscle being supplied by the affected artery starts to
die.
UA/NSTEMI is a type of heart attack in which a
blood clot partly occludes an artery and as a result only a portion of the
heart muscle being supplied by the affected artery dies. UA is one of the types
of ACS, a series of conditions most commonly produced by the rupture of a
plaque in a coronary artery. UA is “unstable” not only because a plaque has
potentially ruptured (a situation which threatens to progress to a myocardial
infarction), but also because the symptoms it produces – the angina – generally
occurs more frequently, often at rest, and lasts longer.
About the PLATO study
PLATO was a large (18,624 patients in 43 countries)
head-to-head patient outcomes study of ticagrelor versus clopidogrel, designed
to establish whether ticagrelor could achieve clinically meaningful CV and
safety end points in ACS patients. PLATO was designed to reflect current
clinical management of ACS patients and included and represented all types of
ACS patients (STEMI, NSTEMI and UA) whether they underwent invasive procedures
or were medically managed.
About BRILINTA™/BRILIQUE™
Ticagrelor (BRILINTA/BRILIQUE) is an
investigational oral antiplatelet treatment for ACS. Ticagrelor is a
direct-acting P2Y12 receptor antagonist in a chemical class called
cyclo-pentyl-triazolo-pyrimidines (CPTPs). Ticagrelor is the first
reversibly-binding oral ADP receptor antagonist.
BRILINTA and BRILIQUE are trademarks of the AstraZeneca group of companies.
About AstraZeneca
AstraZeneca is a global, innovation-driven
biopharmaceutical business with a primary focus on the discovery, development
and commercialisation of prescription medicines. As a leader in
gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation,
oncology and infectious disease medicines, AstraZeneca generated global
revenues of US $32.8 billion in 2009.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners, controlling
shareholders or senior officers as terrorist or terrorist organization or whom
notice had been received that all financial transactions involving their assets
have been blocked or convicted, found guilty or against whom a judgement or
order had been entered in a proceedings for violating money-laundering,
anti-corruption or bribery or international economic or anti-terrorism sanction
laws or whose assets were seized, blocked, frozen or ordered forfeited for
violation of money laundering or international anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper payments
to government officials for engaging in prohibited transactions or with
designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority for
any financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.44.46 |
|
|
1 |
Rs.71.53 |
|
Euro |
1 |
Rs.64.63 |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
5 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
5 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
5 |
|
--PROFITABILIRY |
1~10 |
5 |
|
--LIQUIDITY |
1~10 |
5 |
|
--LEVERAGE |
1~10 |
5 |
|
--RESERVES |
1~10 |
5 |
|
--CREDIT LINES |
1~10 |
5 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
YES |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
45 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this report.
The assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.